Discussing Lower-Risk MDS Treatment Options With Dr. Stahl

In this episode of “Blood Cancer Talks,” hosts Ashwin Kishtagari, MD, and Edward Cliff, MD, are joined by guest Maximilian Stahl, MD, of the Dana-Farber Cancer Institute, to discuss imetelstat and luspatercept for the treatment of lower-risk myelodysplastic syndromes (MDS).

The episode discusses the following trials:

• MEDALIST trial (luspatercept vs placebo)
• COMMANDS trial (luspatercept vs epoetin alfa)
• IMerge trial (imetelstat vs placebo)

This podcast originally appeared on Blood Cancer Talks.